Latest Breaking News On - Armata pharmaceuticals inc - Page 17 : comparemela.com

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Armata Pharmaceuticals Inc for Potential Breaches of Fiduciary Duty By Its Board of Directors

Share this article Share this article NEW YORK, May 13, 2021 /PRNewswire/ Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Armata Pharmaceuticals Inc. (NYSE American: ARMP). If you are a shareholder of Armata Pharmaceuticals Inc. and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at: You may also contact Robert H. Lefkowitz, Esq. either via email at [email protected] or by telephone at 212-725-1000. One of our attorneys will personally speak with you about the case at no cost or obligation.

United statesRoberth lefkowitzArmata pharmaceuticals incPurcell julie lefkowitzPurcell julieArmata pharmaceuticalsPurcell julie amp lefkowitz llpஒன்றுபட்டது மாநிலங்களில்அர்மாட்டா மருந்துகள் இன்க்பர்ஸெல் ஜூலி லேப்கோவித்ஜ்பர்ஸெல் ஜூலிஅர்மாட்டா மருந்துகள்பர்ஸெல் ஜூலி ஆம்ப் லேப்கோவித்ஜ் ல்ப்

Armata Pharmaceuticals Announces First Quarter Results and Provides General Corporate Update

Armata Pharmaceuticals Announces First Quarter Results and Provides General Corporate Update Company earns $750,000 milestone payment related to SWARM-P.a. Study News provided by Share this article Share this article MARINA DEL REY, Calif., May 13, 2021 /PRNewswire/ Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced results for the first quarter of 2021 and provided a corporate update. First Quarter 2021 and Recent Highlights: Continued to advance the single ascending dose (SAD) cohort of the SWARM- P.a. Phase 1b/2a clinical trial evaluating AP-PA02 as a potential treatment for cystic fibrosis patients with chronic

United statesToddr patrickJoyce allaireSteve martinUs department of defenseLifesci advisorsDefense health agencyArmata pharmaceuticals incWarfighter medical research programTherapeutics development awardCf foundationInnoviva incCystic fibrosis cf foundationInnoviva strategic opportunitiesTechnology enterprise consortiumPrnewswire armata pharmaceuticals inc

Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Results and Provides General Corporate Update

Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Results and Provides General Corporate Update
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesMina pastagiaToddr patrickRobinc kramerJoyce allaireSteve martinLifesci advisorsArmata pharmaceuticals incCompany annual report on formInnoviva incInnoviva strategic opportunitiesPrnewswire armata pharmaceuticals incClinical developmentRecent highlightsInvestigational new drugVice president

Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Results and Provides General Corporate Update

Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Results and Provides General Corporate Update
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

United statesMina pastagiaToddr patrickRobinc kramerJoyce allaireSteve martinLifesci advisorsArmata pharmaceuticals incCompany annual report on formInnoviva incInnoviva strategic opportunitiesClinical developmentFourth quarterRecent highlightsInvestigational new drugVice president

Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $20 Million Private Placement with Innoviva

Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $20 Million Private Placement with Innoviva News provided by Share this article Share this article MARINA DEL REY, Calif., March 17, 2021 /PRNewswire/ Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that, following a vote in favor of the transaction by the Armata shareholders, the Company has completed the closing of the second and final tranche of the Company s $20 million private placement of its common stock with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (NASDAQ: INVA) (together, Innoviva ). In connection with the second closing, Armata issued 4,285,935 common shares and 4,285,935 warrants with an exercise price of $3.25 per share, at a per unit price of $3.25 per unit

United statesJoyce allaireSteve martinLifesci advisorsArmata pharmaceuticals incThompson hineWillkie farr gallagherLadenburg thalmann coInnoviva incInnoviva strategic opportunitiesArmata pharmaceuticalsLadenburg thalmannSecurities actAnnual reportInvestor relationsSci advisors